Document is current

Article History

Received: 5 February 2025

Accepted: 1 September 2025

First Online: 18 November 2025

Declarations

:

: All patients provided written informed consent prior to study enrollment.

: All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

: PGP reports speaking fees from Alnylam Pharmaceuticals, AstraZeneca, Bridgebio, Intellia, Ionis Pharmaceuticals, NovoNordisk, and Pfizer, consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, ATTRalus, Bayer, Bridgebio, Intellia, Ionis Pharmaceuticals, Pfizer, Neuroimmune, and NovoNordisk, and research/educational support to my institution from Pfizer, BridgeBio, NovoNordisk, AstraZeneca, Intellia and Alnylam Pharmaceuticals. JMGP reports speaking fees from Pfizer, AstraZeneca, Alnylam Pharmaceuticals, Boehringer-Ingelheim, Abbott, Medtronic, Impulse Dynamics, Novartis, Rovi, and Orion Pharma; consulting fees from Pfizer, Alnylam Pharmaceuticals, and Bristol-Myers Squibb; and research support to his institution from Novartis. PGP and JMGP received honoraria from Pfizer, S.L.U. as coordinators of the PRACTICA study. LB, PT and CP have disclosed that they are full-time employees of Pfizer, S.L.U. and LB, PT and CP have stocks and stock options in Pfizer Inc.